Conversely, preclinical data demonstrated reduced toxicity and improved antitumor efficacy in mice receiving CD19-CAR-T treatment following tafasitamab pretreatment, potentially by modulating CD19 antigen density available for CAR-T binding, thereby ameliorating CAR-T cell activation and pyroptosis of lymphoma cells (99). This evidence concerns the gene CD19 and lymphoma.